Metabolic Stack
GLP-1 + mitochondrial optimization
Why This Stack Works
Tirzepatide acts on GLP-1 and GIP receptors to regulate appetite and glucose. MOTS-C is a mitochondrial-derived peptide that activates AMPK and improves insulin sensitivity at the cellular level. A top-down and bottom-up approach to metabolic health.
This combination draws from Metabolic research, targeting metabolic, weight loss, GLP-1, GIP, dual agonist, insulin. The compounds in this stack act on distinct receptor systems and biological pathways, making them suitable for combined use without mechanism overlap.
All compounds in this stack are supplied by Phiogen with independent third-party Certificate of Analysis (COA) documentation confirming 99%+ purity. They are sold strictly for laboratory and educational use only and are not FDA-approved for human therapeutic use.
Research Protocol
Tirzepatide: 2.5–5 mg/week SC. MOTS-C: 5–10 mg/week SC. Duration: 12–24 weeks.
Stack Components
Tirzepatide 15mg
MetabolicDual GIP/GLP-1 receptor agonist — clinical trials show 20%+ average weight loss.
- 20–22.5% average weight loss in SURMOUNT trials
- Dual GIP + GLP-1 receptor mechanism
- Superior to single GLP-1 agents
- Improved insulin sensitivity and cardiovascular markers
MOTS-c 10mg
MetabolicMitochondria-derived peptide for metabolic regulation, insulin sensitivity, and longevity.
- Enhances insulin sensitivity
- AMPK activation for glucose metabolism
- Mitochondrial function support
- Anti-aging and longevity mechanisms
Frequently Asked Questions
What is the Metabolic Stack?
The Metabolic Stack is a synergistic research peptide protocol designed for glp-1 + mitochondrial optimization. Tirzepatide acts on GLP-1 and GIP receptors to regulate appetite and glucose. MOTS-C is a mitochondrial-derived peptide that activates AMPK and improves insulin sensitivity at the cellular level. A top-down and bottom-up approach to metabolic health.
What is the protocol for the Metabolic Stack?
Tirzepatide: 2.5–5 mg/week SC. MOTS-C: 5–10 mg/week SC. Duration: 12–24 weeks. Note: All compounds are for research and laboratory use only and are not intended for human therapeutic application. Consult the relevant preclinical literature before designing any research protocol.
What compounds are in the Metabolic Stack?
This stack includes Tirzepatide 15mg, MOTS-c 10mg. Key benefits include: Tirzepatide 15mg: 20–22.5% average weight loss in SURMOUNT trials; MOTS-c 10mg: Enhances insulin sensitivity. Each compound targets a distinct mechanism, making them suitable for combined research use without pathway redundancy.
Explore More Stacks
Browse all 9 synergistic peptide protocols or explore the full product catalog.